Cell Cycle Arrest Proteins for Early Diagnosis of Acute Kidney Injury After Lung Transplant (LUTX_AKI)

Cell Cycle Arrest Proteins for Early Diagnosis of Acute Kidney Injury After Lung Transplant: a Prospective Observational Study

Renal failure is a common complication of lung transplant (LUTX). Early diagnosis of acute kidney injury (AKI) in this cohort is of utmost importance, since AKI after LUTX is associated with worsened short and long-term outcomes. To now, early biomarkers of renal failure based on the measurement of cell-cycle arrest proteins have never been tested in this population.

Study Overview

• Status: Recruiting
• Conditions: Acute Kidney Injury
• Intervention / Treatment: Diagnostic test: Nephrocheck (AKI score)

Detailed Description

Bilateral lung transplantation (LUTX) is a surgical procedure offered to patients suffering from chronic respiratory failure. LUTX provides a survival benefit to selected patients but is associated with several short-term and long-term non-pulmonary complications. Acute kidney failure (AKI) is frequent and associated with short-term and long-term morbidity and increased mortality. Indeed, AKI occurs in up to two-thirds of transplanted patients, with 5-13% needing renal replacement therapy (RRT), and associated with mortality ranging from 13 to 50%.

Several risk factors may favor postoperative AKI in patients undergoing LUTX: preoperative (e.g., the patients' preoperative renal function and comorbidities) , intraoperative (i.e., hypoxia, hypotension, massive blood components' transfusions, use of intraoperative extracorporeal membrane oxygenation - ECMO) and postoperative (i.e., use of nephrotoxic agents as tacrolimus and antibiotics).

In patients treated with LUTX, postoperative AKI increases ICU and hospital length of stay and is associated with worsened survival10. At the same time, postoperative AKI is associated with an increase in end-stage renal failure and consequent chronic renal failure11 with potential needs of chronic RRT. Finally, AKI may determine primary graft disfunction with direct and indirect mechanisms (i.e., inability to reach therapeutic targets of anti-rejection drugs).

According to the most recent guidelines (i.e., the Kidney Improving Global Outcomes (KDIGO) criteria), patients are classified as suppering postoperative AKI stage 1, stage 2, and stage 3 are diagnosed whether serum creatinine increases 1.5-1.9 times, 2-2.9 times, and >3 times from the preoperative, respectively. However, these traditional indicators of kidney function have limitations related to early and accurate identification of AKI. Furthermore, sCr has limitations in the specific context of LUTX, both regarding baseline patients' clinical characteristics and surgical. On the one hand, patients enlisted for LUTX are usually undernourished, have reduced muscle mass, reduced protein and creatine intake, which severely limit the sensibility and sensitivity of sCr changes for AKI diagnosis. On the other hand, the need for massive fluid and blood products during LUTX resulting in fluid overload can mask the increase in sCr, delaying the diagnosis of AKI. In addition, early detection of AKI using sCr concentrations is limited by the fact that sCr concentrations increase when renal function has already deteriorated15.

Thus, novel markers capable of early and effective diagnosis of AKI in this patient population are a major clinical interest and may allow to carry out risk-mitigating clinical approaches (e.g., volume optimization, avoid nephrotoxic agents).

Cell Cycle arrest proteins have been suggested as early indicators of AKI. In particular, urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP-7) are biomarkers of the renal tubular cell cycle arrest at the early phase of AKI. The product of the urinary concentrations of TIMP-2 and IGFBP-7 (urinary [TIMP- 2] × [IGFBP-7]) is a promising biomarker for early prediction of AKI in various clinical settings such as out-of-hospital cardiac arrest, in critically ill patients, and following major surgery or emergency department admission .

It is possible to envision the employment of the urinary [TIMP- 2] × [IGFBP-7] index as early indicators of renal failure in patients undergoing LUTX. Thus, with this prospective observational study, the aim of the study is to test the sensitivity and specificity of this index in detecting early AKI in patients undergone LUTX.

Hypothesis/objectives of the study:

In patients undergoing LUTX, the urinary biomarker [TIMP-2] × [IGFBP-7] measured on the first postoperative day after LUTX was evaluated as a reliable early predictive index of postoperative AKI compared to standard KIDGO criteria.

• Study Type: Observational
• Enrollment (Estimated): 40

Contacts and Locations

Study Locations

• Italy
  • Milan, Italy, 20122
    • Recruiting
    • Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico
    • Principal Investigator: Vittorio Scaravilli, MD
    • Contact: Vittorio Scaravilli, MD; Phone Number: 0255033275; Email: vittorio.scaravilli@unimi.it
    • Contact: giacomo grasselli; Phone Number: 0255033275

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All adult undergone primary double lung transplant

Description

Inclusion Criteria:

• Enlistment for bilateral LUTX
• Age > 18 years
• Signed informed consent

Exclusion Criteria:

• Age < 18 years old
• Urgency enlistment
• Already undergone LUTX
• Preoperative use of RRT

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
acute kidney injury	according to KIDGO guidelines	<7 days from lung transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
acute kidney disease	according to KIDGO guidelines	< 90 days from lung transplant

Collaborators and Investigators

• Sponsor: Policlinico Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2022
• Primary Completion (Estimated): December 31, 2023
• Study Completion (Estimated): June 30, 2024

Study Registration Dates

• First Submitted: June 8, 2023
• First Submitted That Met QC Criteria: June 8, 2023
• First Posted (Actual): June 18, 2023

Study Record Updates

• Last Update Posted (Actual): June 22, 2023
• Last Update Submitted That Met QC Criteria: June 19, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: biomarkers; acute kidney injury; lung transplant
• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Wounds and Injuries; Acute Kidney Injury
• Other Study ID Numbers: 127_2022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Upon reasonable request

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No